ATG 037
Alternative Names: ATG-037; ATN-037; CB-708Latest Information Update: 12 Mar 2026
At a glance
- Originator Calithera Biosciences
- Developer Antengene Corporation; Calithera Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Multiple myeloma
- No development reported Haematological malignancies
Most Recent Events
- 24 Feb 2026 Shanghai Junshi Biosciences in collaboration with Antengene Corporation plans a clinical trial of JS 207 in combination with ATG 037 for solid tumours in Chinese Mainland
- 24 Feb 2026 Shanghai Junshi Biosciences and Antengene Corporation agree to co-develop JS207 in combination with ATG-037 in China for Solid tumours
- 24 Feb 2026 Efficacy and adverse events data from a phase I/II STAMINA-01 trial in solid tumours released by Shanghai Junshi Biosciences